Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$167.22
-0.4%
$208.84
$163.33
$251.99
$47.93B0.311.86 million shs4.13 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$102.87
-0.4%
$98.68
$71.88
$107.17
$152.19B0.686.34 million shs3.61 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$84.66
-0.8%
$71.08
$57.52
$132.26
$33.20B1.434.33 million shs3.35 million shs
Stryker Co. stock logo
SYK
Stryker
$380.87
-0.4%
$365.47
$314.93
$406.19
$145.37B0.931.36 million shs758,784 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.00%-0.82%-16.03%-27.37%-28.41%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.00%-1.97%+11.38%-2.34%+41.46%
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+3.72%+25.79%-3.88%-33.56%
Stryker Co. stock logo
SYK
Stryker
0.00%+0.60%+9.75%-2.70%+15.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9287 of 5 stars
4.23.03.34.02.73.31.3
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.5441 of 5 stars
3.53.00.04.23.52.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.7259 of 5 stars
3.54.00.04.72.72.51.9
Stryker Co. stock logo
SYK
Stryker
4.8263 of 5 stars
3.43.03.34.23.92.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.45
Hold$231.4438.41% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.08
Buy$114.5211.33% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.1115.89% Upside
Stryker Co. stock logo
SYK
Stryker
2.79
Moderate Buy$427.0512.12% Upside

Current Analyst Ratings Breakdown

Latest BDX, SYK, BSX, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $196.00
5/5/2025
Stryker Co. stock logo
SYK
Stryker
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$450.00
5/5/2025
DexCom, Inc. stock logo
DXCM
DexCom
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.00
5/5/2025
Stryker Co. stock logo
SYK
Stryker
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$390.00 ➝ $400.00
5/5/2025
Stryker Co. stock logo
SYK
Stryker
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$280.00 ➝ $224.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$260.00 ➝ $185.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$192.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/2/2025
DexCom, Inc. stock logo
DXCM
DexCom
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $90.00
(Data available from 5/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.87B2.30$15.54 per share10.76$89.57 per share1.87
Boston Scientific Co. stock logo
BSX
Boston Scientific
$17.55B8.67$3.56 per share28.86$14.91 per share6.90
DexCom, Inc. stock logo
DXCM
DexCom
$4.15B8.00$2.13 per share39.75$5.38 per share15.74
Stryker Co. stock logo
SYK
Stryker
$23.22B6.26$14.87 per share25.62$54.08 per share7.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2427.7810.691.638.47%15.74%7.29%N/A
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.85B$1.3782.3031.852.7911.07%17.80%9.85%7/23/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3459.2034.412.3014.29%30.14%10.11%7/24/2025 (Estimated)
Stryker Co. stock logo
SYK
Stryker
$2.99B$7.4049.0825.682.9313.25%23.58%11.37%7/29/2025 (Estimated)

Latest BDX, SYK, BSX, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
5/1/2025Q1 2025
Stryker Co. stock logo
SYK
Stryker
$2.73$2.84+$0.11$1.69$5.68 billion$5.87 billion
4/23/2025Q1 2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
2/13/2025Q4 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.50$0.45-$0.05$0.38$1.10 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.49%+5.00%79.39%53 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
$3.360.88%+7.82%45.41%32 Years

Latest BDX, SYK, BSX, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2025
Stryker Co. stock logo
SYK
Stryker
quarterly$0.840.88%6/30/20256/30/20257/31/2025
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.13
0.63
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.41
1.08
1.02
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
Stryker Co. stock logo
SYK
Stryker
0.59
1.95
1.32

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Stryker Co. stock logo
SYK
Stryker
77.09%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Stryker Co. stock logo
SYK
Stryker
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000286.61 million286.10 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
45,0001.48 billion1.47 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600392.11 million389.60 millionOptionable
Stryker Co. stock logo
SYK
Stryker
51,000381.69 million359.07 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$167.22 -0.73 (-0.43%)
As of 05/9/2025 03:59 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$102.87 -0.42 (-0.41%)
As of 05/9/2025 03:53 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$84.66 -0.68 (-0.80%)
As of 05/9/2025 03:58 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Stryker stock logo

Stryker NYSE:SYK

$380.87 -1.59 (-0.42%)
As of 05/9/2025 03:59 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.